On August 7, 2017 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) reported a collaboration with Kyukyu Pharmaceutical Co., Ltd. (hereafter, Kyukyu Pharmaceutical) to commercialize generic transdermal fentanyl citrate patches for long-acting cancer pain relief (Press release, Daiichi Sankyo, AUG 7, 2017, View Source [SID1234520062]).

The fentanyl citrate patches are a once-daily transdermal opioid analgesic for treatment of moderate to severe cancer pain, and are a generic formulation of Fentos Tape.

Kyukyu Pharmaceutical is currently applying for marketing authorization from the Japanese Ministry of Health, Labour and Welfare. Following the successful obtainment of that authorization, Kyukyu Pharmaceutical will handle manufacturing, and Daiichi Sankyo will handle marketing and promotion activities, for this product.

Daiichi Sankyo expects that the commercialization of generic transdermal fentanyl citrate patches will help to expand our product lineup of opioid analgesics and will offer a novel treatment option to cancer patients and healthcare providers in Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!